Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has been given an average rating of “Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports.

Highlights,Mixed professional viewpoints accompany Phathom Pharmaceuticals.,Company officials have adjusted their share positions.,Institutional investment activity remains robust.,In the ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

Originally available to stream on a dedicated app, “The Chosen” chose to premiere its third and fourth seasons in theaters via Fathom Entertainment — an unprecedented move for an entire ...

Goldman Sachs lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $12 from $18 and keeps a Neutral rating on the shares after its FY24 results. The company’s product revenue ...

Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $19 from $27 and keeps a Buy rating on the shares. The firm notes Phathom’s Q4 ...

Revenue: US$55.3m (up by US$54.6m from FY 2023). Net loss: US$334.3m (loss widened by 66% from FY 2023). US$5.29 loss per share (further deteriorated from US$3.93 loss in FY 2023). Revenue ...

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) secured FDA approval for non-erosive GERD, enhancing their product portfolio. The company reported strong commercial coverage, with over 120 million lives ...

Phathom Pharmaceuticals Inc (PHAT) reported a significant increase in revenue for Q4 2024, with net revenues reaching $29.7 million, marking an 81% sequential increase. Despite the positive revenue ...

Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. At this time, all participants are in a listen-only mode. After the presentation ...

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.